Jounce Taps Ex-Ariad Dealmaker, Cole, as CBO

Xconomy Boston — 

Cambridge, MA-based cancer drug developer Jounce Therapeutics (NASDAQ: JNCE) has named Hugh Cole its new chief business officer and head of corporate development. Cole was previously a top dealmaker at Ariad Pharmaceuticals and was a Shire executive for seven years before that. Takeda acquired Ariad for $5.2 billion in January.